Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Phase 1 Active not recruiting 8 enrolled Stanford University Kite, A Gilead Company · collab

NaSingle-groupOpen-labelTreatment

Summary

To assess the feasibility of oral dasatinib pulses (3 consecutive days per week) during the first month following infusion of brexucabtagene autoleucel (Tecartus) in adults with relapsed or refractory B-cell acute lymphoblastic leukemia.

Timeline

Start: 2023-10-02
Primary completion: 2027-06
Completion: 2027-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	dasatinib anhydrous	Small molecule	100 mg	Oral

Study of Brexucabtagene Autoleucel Plus Dasatinib in Adults With Acute Lymphoblastic Leukemia

Summary

Timeline

Drugs

Indications